CD4 and anemia: In general 205(70.71%) of the study participants were anemic and 100(40.46%) had moderate to severe anemia, which was mostly macrocytic in type (37.86 vs. 11.17%, p=0.001) and was independently associated with AZT based regimen (OR=3.3, p=0.005), advanced clinical stage (OR=5.3, p<0.001) and low baseline CD4 count (OR=2.27, p=0.003).